Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is characterized by overexpression of epidermal growth factor receptor (EGFR) and activation of its downstream signaling pathways. Dual targeting of EGFR using one monoclonal antibody (mAb; cetuximab or panitumumab) and one tyrosine kinase inhibitor (EGFR-TKI; ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerrab, Abderrahim El, Bamdad, Mahchid, Kwiatkowski, Fabrice, Bignon, Yves-Jean, Penault-Llorca, Frédérique, Aubel, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342003/
https://www.ncbi.nlm.nih.gov/pubmed/27655662
http://dx.doi.org/10.18632/oncotarget.12037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342003/
https://www.ncbi.nlm.nih.gov/pubmed/27655662
http://dx.doi.org/10.18632/oncotarget.12037

Ejemplares similares